Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1863 1
1873 2
1874 1
1996 1
1997 1
2000 1
2001 1
2002 1
2003 6
2004 5
2005 9
2006 14
2007 4
2008 11
2009 14
2010 7
2011 8
2012 17
2013 9
2014 9
2015 5
2016 5
2017 6
2018 7
2019 5
2020 1
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 16339289

128 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD. Reginster JY, et al. Ann Rheum Dis. 2006 May;65(5):654-61. doi: 10.1136/ard.2005.044958. Epub 2005 Dec 8. Ann Rheum Dis. 2006. PMID: 16339289 Free PMC article. Clinical Trial.
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S. Emkey R, et al. Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018. Clin Ther. 2009. PMID: 19446148 Clinical Trial.
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C. Brown JP, et al. Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28. Osteoporos Int. 2014. PMID: 24676847
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. Miller PD, et al. J Bone Miner Res. 2005 Aug;20(8):1315-22. doi: 10.1359/JBMR.050313. Epub 2005 Mar 14. J Bone Miner Res. 2005. PMID: 16007327 Free article. Clinical Trial.
128 results